

**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.111

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

**Editorial**

- 321** Spondyloarthritis: may the force be with you?  
*D McGonagle, R C Thomas, G Schett*

**Viewpoint**

- 324** Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?  
*U Müller-Ladner, A Tyndall, L Czirjak, C Denton, M Maticci-Cerinic, on behalf of EUSTAR centres*

**Recommendation**

- 328** Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative  
*F Sivera, M Andrés, L Carmona, A S R Kydd, J Moi, R Seth, M Srinanganathan, C van Durme, I van Ecteld, O Vinile, M D Wechalekar, D Aletaha, C Bombardier, R Buchbinder, C J Edwards, R B Landewé, J W Bijlsma, J C Branco, R Burgos-Vargas, A I Catrina, D Elewaut, A J L Ferrari, P Kiely, B F Leeb, C Montecucco, U Müller-Ladner, M Ostergaard, J Zochling, L Falzon, D M van der Heijde*

**Review**

- 336** The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?  
*M A Karsdal, A C Bay-Jensen, R J Lories, S Abramson, T Spector, P Pastoureau, C Christiansen, M Attur, K Henriksen, S R Goldring, V Kraus*

**Clinical and epidemiological research**

- 349** Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial  
*I B McInnes, J Sieper, J Braun, P Emery, D van der Heijde, J D Isaacs, G Dahmen, J Wollenhaupt, H Schulze-Koops, J Kogan, S Ma, M M Schumacher, A P Bertolino, W Hueber, P P Tak*
- 357** Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity—patient outcomes from a 2-year, randomised controlled trial  
*J Prindahl, J Sørensen, H C Horn, R Petersen, K Hørslev-Petersen*
- 365** Metric properties of advanced imaging methods in osteoarthritis of the hand: a systematic review  
*M S Saltzher, R W Selles, S M A Bierna-Zeinstra, G S R Muradin, J H Coert, J W van Neck, J J Luime*
- 376** Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study  
*E Maheu, C Cadet, M Marry, D Moysé, I Kerloch, P Coste, M Dougados, B Mazières, T D Spector, H Halhol, J-M Grouin, M Lequesne*
- 385** Low-dose aspirin use and recurrent gout attacks  
*Y Zhang, T Neogi, C Chen, C Chaisson, D J Hunter, H Choi*
- 391** Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias  
*L H D van Tuyl, D van der Heijde, D L Knol, M Boers*

- 396** Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)  
*J van Aken, L Heimans, H Gillet-van Dongen, K Visser, H K Ronday, I Speyer, A J Peeters, T W J Huizinga, C F Allaart*

- 401** Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus  
*R Mina, M S Klein-Gielman, S Nelson, B A Eberhard, G Higgins, N G Singer, K Onel, L Tucker, K M O'Neil, M Punaro, D M Levy, K Haines, A Martini, N Ruperto, D Lovell, H I Brunner*

- 407** Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)  
*E Theander, T Husmark, G-M Alenius, P T Larsson, A Teleman, M Gejzer, U R C Lindqvist*

- 414** Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials  
*R Goulabchand, G Mouterde, T Barnetche, C Lukas, J Morel, B Combe*

- 420** The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis  
*G Abignano, G Cuomo, M H Buch, W M Rosenberg, G Valentini, P Emery, F D Galdo*

- 428** Long-term outcome of Rheumatoid Arthritis defined according to the 2010-classification criteria  
*L E Burgers, J A B van Nies, L Y Ho, D P C de Rooy, T W J Huizinga, A H M van der Helm-van Mil*

- 433** Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women  
*K M J A Claessen, M Kloppenburg, H M Kroon, J Bijsterbosch, A M Pereira, J A Romijn, T van der Straaten, R G H H Nelissen, A Hofman, A G Uitterlinden, B J Duijnisveld, N Lakenberg, M Beekman, J B van Meurs, P E Slagboom, N R Biermasz, I Meulenbelt*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.  
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

**Basic and translational research**

- 437** Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells



*P Jacques, S Lambrecht, E Verheugen, E Pauwels, G Kollias, M Armaka, M Verhoye, A Van der Linden, R Achten, R J Lories, D Elewaut*

- 446** A synthetic PPAR- $\gamma$  agonist triterpenoid ameliorates experimental fibrosis: PPAR- $\gamma$ -independent suppression of fibrotic responses

*J Wei, H Zhu, K Komura, G Lord, M Tomcik, W Wang, S Doniparthi, Z Tamaki, M Hinchcliff, J H W Distler, J Varga*

- 455** MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease

*M Stoffels, A Szperl, A Simon, M G Netea, T S Plantinga, M van Deuren, S Kamphuis, H J Lachmann, E Cuppen, W P Kloosterman, J Frenkel, C C van Diemen, C Wijmenga, M van Gijn, J W M van der Meer*

- 462** Increased NLRP3-dependent interleukin 1 $\beta$  secretion in patients with familial Mediterranean fever: correlation with MEFV genotype

*A Omenetti, S Carta, L Delfino, A Martini, M Gattorno, A Rubartelli*

**Letters**

- 470** Comparison of initial versus delayed introduction of a treat-to-target strategy in patients with recent-onset rheumatoid arthritis: results of the T-4 3-year study

*Y Urata, Y Nakamura, Ken-ichi Furukawa*

- 472** EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

*R V Moerman, S Arends, P M Meiners, E Brouwer, F K L Spijkervet, F G M Kroese, A Vissink, H Bootsma*

- 474** Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen

*B Tedeschi, L Arnaud, M Hie, A Mathian, Z Amoura*

- 475** Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease

*D J Birmingham, G Shidham, A Perna, D M Fine, M Bissell, R Rodby, G Remuzzi, M Petri, P Hebert, B H Rovin, L A Hebert*

**Electronic pages**

- e6** 'Is (creno)balneotherapy a drug, a surgical procedure or a non-pharmacological treatment?' eLetter on EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis

*R J Forestier, F B Erol*

- e7** Response to Dr Forestier's eLetter on EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis

*T P V Vlieland, L Fernandes, J W Bijlsma, K B Hagen, on behalf of the Task Force on Eular recommendations for the non-pharmacological core management of hip and knee osteoarthritis*

- e8** Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomised, placebo-controlled trial

*J-Y Reginster*

- e9** Response to Dr Bolland's eLetter: Strontium and cardiovascular events

*J Y Reginster*